AB0096 Presence of ACPA and RF Autoantibodies in Ulcerative Colitis and Crohn's Disease

BackgroundPresence of arthritis autoantibodies is specific for rheumatoid arthritis (RA). Anti-citrullinated peptide antibodies (ACPA) and rheumatoid factor (RF) can be detected several years before the onset of arthritis and are thought to have a pathogenic role. However, where and when autoantibod...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2016-06, Vol.75 (Suppl 2), p.929-930
Hauptverfasser: Janssen, K.M.J., Hop, H., Vissink, A., Dijkstra, G., Brouwer, E., Westra, J.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 930
container_issue Suppl 2
container_start_page 929
container_title Annals of the rheumatic diseases
container_volume 75
creator Janssen, K.M.J.
Hop, H.
Vissink, A.
Dijkstra, G.
Brouwer, E.
Westra, J.
description BackgroundPresence of arthritis autoantibodies is specific for rheumatoid arthritis (RA). Anti-citrullinated peptide antibodies (ACPA) and rheumatoid factor (RF) can be detected several years before the onset of arthritis and are thought to have a pathogenic role. However, where and when autoantibody production starts is unclear. A potential trigger could be chronic mucosal inflammation as in inflammatory bowel disease (IBD) since the gut microbiome is thought to be involved in induction of (auto) immunity. This assumption is supported by the demonstration of citrullinated proteins in intestinal tissue of IBD patients.ObjectivesTo assess the prevalence of ACPA and RF in IBD patients as well as to assess the prevalence of joint complaints in autoantibody positive versus autoantibody negative IBD patients.MethodsSerum was collected from 227 patients with ulcerative colitis (UC) and 164 with Crohn's disease (CD) participating in the Dutch IBD pearl chain institute biobank initiative. Baseline disease characteristics including enthesitis, arthralgia, arthritis and comorbid conditions like spondylarthropathy were obtained from medical electronic records. IgG and IgA ACPA levels were measured by anti-CCP2 ELISA from EuroDiagnostica (ED) and IgM and IgA-RF levels were measured by in-house ELISA. The cut-off value for IgG ACPA positivity was 2 U/mL and for IgA ACPA 1.04 aU/ml based on the mean +2SD of a group of healthy reference samples. Seropositivity for IgM and IgA-RF was defined at ≥10 IU/ml and ≥25 IU/ml, respectively.ResultsThirty-two (14.1%) UC and 33 (20.1%) CD patients had an IgG ACPA level >2 U/ml. However, all IgG ACPA levels were below the diagnostic cut off level for RA which is set at ≥25 U/ml. IgA ACPA levels were increased in 83 (36.5%) UC and 48 (29.3%) CD patients. IgM-RF seropositivity was observed in 11 (4.8%) UC and 6 (3.7%) CD patients. IgA-RF seropositivity was observed in 6 (2.6%) UC and 8 (4.9%) CD patients. A total of 101 (44.5%) UC and 76 (46.3%) CD were seropositive for at least 1 arthritis autoantibody. Arthralgias were reported in 19.1% of UC and 33.3% of CD, respectively. Among patients with arthralgias, the percentage of individuals being seropositive for 1 or more autoantibodies was comparable to patients without arthralgias.ConclusionsThe results of our study support the hypothesis that inflammation of intestinal mucosa induces low systemic levels of ACPA, which eventually may play a role in induction of RA. However, the developm
doi_str_mv 10.1136/annrheumdis-2016-eular.4071
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1901881824</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4322516067</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1854-b8b2915e01cbaef251fcfa4b3618e4ee14bb930ef4c9e45e30b5c01d1744f07f3</originalsourceid><addsrcrecordid>eNqVkMFKw0AQhhdRsFbfYaEHT6kzySZN8BSjVaFgEXvwtOyms3RLmtTdRPDmxRf1SUxbD149DTP83wzzMTZCGCNGyZWqa7eibrO0PggBk4C6SrmxgAkesQGKJO3HCRyzAQBEgciSySk7837dt5BiOmCv-Q1Alnx_fs0deapL4o3heTHPuaqX_HnK865tVN1a3SwteW5rvqhKcqq178SLprKt9fts4ZpVfen5rfWkPJ2zE6MqTxe_dcgW07uX4iGYPd0_Fvks0JjGItCpDjOMCbDUikwYoymNEjpKMCVBhELrLAIyosxIxBSBjkvAJU6EMDAx0ZCNDnu3rnnryLdy3XSu7k9KzADT_s1Q9KnrQ6p0jfeOjNw6u1HuQyLInUv5x6XcuZR7l3LnsqeTA60363-BP4Cof4Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1901881824</pqid></control><display><type>article</type><title>AB0096 Presence of ACPA and RF Autoantibodies in Ulcerative Colitis and Crohn's Disease</title><source>BMJ Journals - NESLi2</source><creator>Janssen, K.M.J. ; Hop, H. ; Vissink, A. ; Dijkstra, G. ; Brouwer, E. ; Westra, J.</creator><creatorcontrib>Janssen, K.M.J. ; Hop, H. ; Vissink, A. ; Dijkstra, G. ; Brouwer, E. ; Westra, J.</creatorcontrib><description>BackgroundPresence of arthritis autoantibodies is specific for rheumatoid arthritis (RA). Anti-citrullinated peptide antibodies (ACPA) and rheumatoid factor (RF) can be detected several years before the onset of arthritis and are thought to have a pathogenic role. However, where and when autoantibody production starts is unclear. A potential trigger could be chronic mucosal inflammation as in inflammatory bowel disease (IBD) since the gut microbiome is thought to be involved in induction of (auto) immunity. This assumption is supported by the demonstration of citrullinated proteins in intestinal tissue of IBD patients.ObjectivesTo assess the prevalence of ACPA and RF in IBD patients as well as to assess the prevalence of joint complaints in autoantibody positive versus autoantibody negative IBD patients.MethodsSerum was collected from 227 patients with ulcerative colitis (UC) and 164 with Crohn's disease (CD) participating in the Dutch IBD pearl chain institute biobank initiative. Baseline disease characteristics including enthesitis, arthralgia, arthritis and comorbid conditions like spondylarthropathy were obtained from medical electronic records. IgG and IgA ACPA levels were measured by anti-CCP2 ELISA from EuroDiagnostica (ED) and IgM and IgA-RF levels were measured by in-house ELISA. The cut-off value for IgG ACPA positivity was 2 U/mL and for IgA ACPA 1.04 aU/ml based on the mean +2SD of a group of healthy reference samples. Seropositivity for IgM and IgA-RF was defined at ≥10 IU/ml and ≥25 IU/ml, respectively.ResultsThirty-two (14.1%) UC and 33 (20.1%) CD patients had an IgG ACPA level &gt;2 U/ml. However, all IgG ACPA levels were below the diagnostic cut off level for RA which is set at ≥25 U/ml. IgA ACPA levels were increased in 83 (36.5%) UC and 48 (29.3%) CD patients. IgM-RF seropositivity was observed in 11 (4.8%) UC and 6 (3.7%) CD patients. IgA-RF seropositivity was observed in 6 (2.6%) UC and 8 (4.9%) CD patients. A total of 101 (44.5%) UC and 76 (46.3%) CD were seropositive for at least 1 arthritis autoantibody. Arthralgias were reported in 19.1% of UC and 33.3% of CD, respectively. Among patients with arthralgias, the percentage of individuals being seropositive for 1 or more autoantibodies was comparable to patients without arthralgias.ConclusionsThe results of our study support the hypothesis that inflammation of intestinal mucosa induces low systemic levels of ACPA, which eventually may play a role in induction of RA. However, the development of arthralgias in IBD patients is independent on the presence of low systemic presence of arthritis autoantibodies.Disclosure of InterestNone declared</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2016-eular.4071</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><ispartof>Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.929-930</ispartof><rights>2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2016 (c) 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b1854-b8b2915e01cbaef251fcfa4b3618e4ee14bb930ef4c9e45e30b5c01d1744f07f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/75/Suppl_2/929.3.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/75/Suppl_2/929.3.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,780,784,3195,23570,27923,27924,77471,77502</link.rule.ids></links><search><creatorcontrib>Janssen, K.M.J.</creatorcontrib><creatorcontrib>Hop, H.</creatorcontrib><creatorcontrib>Vissink, A.</creatorcontrib><creatorcontrib>Dijkstra, G.</creatorcontrib><creatorcontrib>Brouwer, E.</creatorcontrib><creatorcontrib>Westra, J.</creatorcontrib><title>AB0096 Presence of ACPA and RF Autoantibodies in Ulcerative Colitis and Crohn's Disease</title><title>Annals of the rheumatic diseases</title><description>BackgroundPresence of arthritis autoantibodies is specific for rheumatoid arthritis (RA). Anti-citrullinated peptide antibodies (ACPA) and rheumatoid factor (RF) can be detected several years before the onset of arthritis and are thought to have a pathogenic role. However, where and when autoantibody production starts is unclear. A potential trigger could be chronic mucosal inflammation as in inflammatory bowel disease (IBD) since the gut microbiome is thought to be involved in induction of (auto) immunity. This assumption is supported by the demonstration of citrullinated proteins in intestinal tissue of IBD patients.ObjectivesTo assess the prevalence of ACPA and RF in IBD patients as well as to assess the prevalence of joint complaints in autoantibody positive versus autoantibody negative IBD patients.MethodsSerum was collected from 227 patients with ulcerative colitis (UC) and 164 with Crohn's disease (CD) participating in the Dutch IBD pearl chain institute biobank initiative. Baseline disease characteristics including enthesitis, arthralgia, arthritis and comorbid conditions like spondylarthropathy were obtained from medical electronic records. IgG and IgA ACPA levels were measured by anti-CCP2 ELISA from EuroDiagnostica (ED) and IgM and IgA-RF levels were measured by in-house ELISA. The cut-off value for IgG ACPA positivity was 2 U/mL and for IgA ACPA 1.04 aU/ml based on the mean +2SD of a group of healthy reference samples. Seropositivity for IgM and IgA-RF was defined at ≥10 IU/ml and ≥25 IU/ml, respectively.ResultsThirty-two (14.1%) UC and 33 (20.1%) CD patients had an IgG ACPA level &gt;2 U/ml. However, all IgG ACPA levels were below the diagnostic cut off level for RA which is set at ≥25 U/ml. IgA ACPA levels were increased in 83 (36.5%) UC and 48 (29.3%) CD patients. IgM-RF seropositivity was observed in 11 (4.8%) UC and 6 (3.7%) CD patients. IgA-RF seropositivity was observed in 6 (2.6%) UC and 8 (4.9%) CD patients. A total of 101 (44.5%) UC and 76 (46.3%) CD were seropositive for at least 1 arthritis autoantibody. Arthralgias were reported in 19.1% of UC and 33.3% of CD, respectively. Among patients with arthralgias, the percentage of individuals being seropositive for 1 or more autoantibodies was comparable to patients without arthralgias.ConclusionsThe results of our study support the hypothesis that inflammation of intestinal mucosa induces low systemic levels of ACPA, which eventually may play a role in induction of RA. However, the development of arthralgias in IBD patients is independent on the presence of low systemic presence of arthritis autoantibodies.Disclosure of InterestNone declared</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqVkMFKw0AQhhdRsFbfYaEHT6kzySZN8BSjVaFgEXvwtOyms3RLmtTdRPDmxRf1SUxbD149DTP83wzzMTZCGCNGyZWqa7eibrO0PggBk4C6SrmxgAkesQGKJO3HCRyzAQBEgciSySk7837dt5BiOmCv-Q1Alnx_fs0deapL4o3heTHPuaqX_HnK865tVN1a3SwteW5rvqhKcqq178SLprKt9fts4ZpVfen5rfWkPJ2zE6MqTxe_dcgW07uX4iGYPd0_Fvks0JjGItCpDjOMCbDUikwYoymNEjpKMCVBhELrLAIyosxIxBSBjkvAJU6EMDAx0ZCNDnu3rnnryLdy3XSu7k9KzADT_s1Q9KnrQ6p0jfeOjNw6u1HuQyLInUv5x6XcuZR7l3LnsqeTA60363-BP4Cof4Y</recordid><startdate>201606</startdate><enddate>201606</enddate><creator>Janssen, K.M.J.</creator><creator>Hop, H.</creator><creator>Vissink, A.</creator><creator>Dijkstra, G.</creator><creator>Brouwer, E.</creator><creator>Westra, J.</creator><general>BMJ Publishing Group LTD</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope></search><sort><creationdate>201606</creationdate><title>AB0096 Presence of ACPA and RF Autoantibodies in Ulcerative Colitis and Crohn's Disease</title><author>Janssen, K.M.J. ; Hop, H. ; Vissink, A. ; Dijkstra, G. ; Brouwer, E. ; Westra, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1854-b8b2915e01cbaef251fcfa4b3618e4ee14bb930ef4c9e45e30b5c01d1744f07f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Janssen, K.M.J.</creatorcontrib><creatorcontrib>Hop, H.</creatorcontrib><creatorcontrib>Vissink, A.</creatorcontrib><creatorcontrib>Dijkstra, G.</creatorcontrib><creatorcontrib>Brouwer, E.</creatorcontrib><creatorcontrib>Westra, J.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Janssen, K.M.J.</au><au>Hop, H.</au><au>Vissink, A.</au><au>Dijkstra, G.</au><au>Brouwer, E.</au><au>Westra, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>AB0096 Presence of ACPA and RF Autoantibodies in Ulcerative Colitis and Crohn's Disease</atitle><jtitle>Annals of the rheumatic diseases</jtitle><date>2016-06</date><risdate>2016</risdate><volume>75</volume><issue>Suppl 2</issue><spage>929</spage><epage>930</epage><pages>929-930</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>BackgroundPresence of arthritis autoantibodies is specific for rheumatoid arthritis (RA). Anti-citrullinated peptide antibodies (ACPA) and rheumatoid factor (RF) can be detected several years before the onset of arthritis and are thought to have a pathogenic role. However, where and when autoantibody production starts is unclear. A potential trigger could be chronic mucosal inflammation as in inflammatory bowel disease (IBD) since the gut microbiome is thought to be involved in induction of (auto) immunity. This assumption is supported by the demonstration of citrullinated proteins in intestinal tissue of IBD patients.ObjectivesTo assess the prevalence of ACPA and RF in IBD patients as well as to assess the prevalence of joint complaints in autoantibody positive versus autoantibody negative IBD patients.MethodsSerum was collected from 227 patients with ulcerative colitis (UC) and 164 with Crohn's disease (CD) participating in the Dutch IBD pearl chain institute biobank initiative. Baseline disease characteristics including enthesitis, arthralgia, arthritis and comorbid conditions like spondylarthropathy were obtained from medical electronic records. IgG and IgA ACPA levels were measured by anti-CCP2 ELISA from EuroDiagnostica (ED) and IgM and IgA-RF levels were measured by in-house ELISA. The cut-off value for IgG ACPA positivity was 2 U/mL and for IgA ACPA 1.04 aU/ml based on the mean +2SD of a group of healthy reference samples. Seropositivity for IgM and IgA-RF was defined at ≥10 IU/ml and ≥25 IU/ml, respectively.ResultsThirty-two (14.1%) UC and 33 (20.1%) CD patients had an IgG ACPA level &gt;2 U/ml. However, all IgG ACPA levels were below the diagnostic cut off level for RA which is set at ≥25 U/ml. IgA ACPA levels were increased in 83 (36.5%) UC and 48 (29.3%) CD patients. IgM-RF seropositivity was observed in 11 (4.8%) UC and 6 (3.7%) CD patients. IgA-RF seropositivity was observed in 6 (2.6%) UC and 8 (4.9%) CD patients. A total of 101 (44.5%) UC and 76 (46.3%) CD were seropositive for at least 1 arthritis autoantibody. Arthralgias were reported in 19.1% of UC and 33.3% of CD, respectively. Among patients with arthralgias, the percentage of individuals being seropositive for 1 or more autoantibodies was comparable to patients without arthralgias.ConclusionsThe results of our study support the hypothesis that inflammation of intestinal mucosa induces low systemic levels of ACPA, which eventually may play a role in induction of RA. However, the development of arthralgias in IBD patients is independent on the presence of low systemic presence of arthritis autoantibodies.Disclosure of InterestNone declared</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/annrheumdis-2016-eular.4071</doi><tpages>2</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0003-4967
ispartof Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.929-930
issn 0003-4967
1468-2060
language eng
recordid cdi_proquest_journals_1901881824
source BMJ Journals - NESLi2
title AB0096 Presence of ACPA and RF Autoantibodies in Ulcerative Colitis and Crohn's Disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T17%3A45%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=AB0096%E2%80%85Presence%20of%20ACPA%20and%20RF%20Autoantibodies%20in%20Ulcerative%20Colitis%20and%20Crohn's%20Disease&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Janssen,%20K.M.J.&rft.date=2016-06&rft.volume=75&rft.issue=Suppl%202&rft.spage=929&rft.epage=930&rft.pages=929-930&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2016-eular.4071&rft_dat=%3Cproquest_cross%3E4322516067%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1901881824&rft_id=info:pmid/&rfr_iscdi=true